Wegovy for obesity
How Wegovy (semaglutide) is used in obesity, what the clinical evidence shows, and how it compares to other treatment options.
Obesity: what it is
Obesity is a chronic disease defined by excess body fat that increases the risk of cardiovascular disease, type 2 diabetes, and other comorbidities. The American Medical Association recognized obesity as a disease in 2013. Standard threshold: BMI ≥30 (or ≥27 with a weight-related condition).
How Wegovy fits into obesity treatment
First-line: lifestyle modification (calorie deficit, structured physical activity, behavioral counseling). Pharmacotherapy is indicated for BMI ≥30 or ≥27 with comorbidity. GLP-1 receptor agonists (semaglutide/Wegovy, liraglutide/Saxenda) and the dual GLP-1/GIP agonist tirzepatide (Zepbound) are now first-line drug therapy due to 14-22% mean body-weight reduction in trials. Older agents (phentermine, naltrexone-bupropion, orlistat) remain options. Bariatric surgery for BMI ≥40 or ≥35 with severe comorbidity.
Wegovy works by: Semaglutide mimics GLP-1, a gut hormone released after meals. It slows stomach emptying (you feel full longer), suppresses appetite (reduced food-noise signaling in the brain), and improves insulin sensitivity. The combined effect is sustained appetite reduction and meaningful weight loss for most patients.
Who qualifies for Wegovy for obesity
FDA-approved for adults with BMI ≥30, or BMI ≥27 with a weight-related comorbidity (high blood pressure, prediabetes, sleep apnea, dyslipidemia). Also approved for adolescents 12+ at the 95th percentile BMI. Contraindicated in personal/family history of medullary thyroid cancer or MEN2.
Clinical evidence
14.9% mean body-weight reduction at 68 weeks
Trial: STEP 1 (NCT03548935) · vs 2.4% with placebo + lifestyle · N = 1,961
How Wegovy compares to other obesity treatments
Zepbound for obesity
Dual GLP-1/GIP agonist for weight management. ~20% body weight loss in trials — strongest weight-loss drug cur…
Saxenda for obesity
FDA-approved daily injectable liraglutide for chronic weight management. Older-generation GLP-1, daily dosing.…
Compounded semaglutide for obesity
Custom-compounded semaglutide. Cheaper than branded Wegovy. Not FDA-approved; legal landscape shifts.…
Compounded tirzepatide for obesity
Custom-compounded tirzepatide. Cheaper than Zepbound/Mounjaro. Not FDA-approved.…
Frequently asked about obesity
- Is obesity considered a disease?
- Yes. The American Medical Association formally recognized obesity as a disease in 2013, and the World Health Organization classifies it as a chronic condition. This framing matters clinically (it justifies long-term treatment) and financially (it supports insurance coverage of pharmacotherapy).
- How much weight loss is clinically meaningful?
- 5-10% body-weight reduction sustained for 6+ months produces measurable improvement in blood pressure, lipids, glucose control, and quality of life. GLP-1 trials produce 14-22% mean weight loss — well above the threshold for clinical benefit.
- Do I need to fail diet and exercise before getting a GLP-1?
- Clinical guidelines no longer require documented failure of lifestyle intervention before initiating pharmacotherapy if BMI criteria are met. Many insurance plans, however, do require documented prior attempts. A program with an insurance concierge handles this paperwork for you.
- Will I have to take a GLP-1 forever?
- Trial extension data shows roughly two-thirds of lost weight returns within 12-18 months of discontinuation. The clinical model is chronic-disease treatment, similar to managing hypertension or hyperlipidemia. Some patients move to a lower maintenance dose rather than a full stop.